Clinical Study

Ea5182- Osimertinib With Or Without Bevacizumab As Initial Treatment For Patients With Egfr-Mutant Lung Cancer

Posted Date: May 13, 2021

  • Investigator: Christopher Lemmon
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The main purpose of this study is to compare the effect of bevacizumab and AZD9291 (osimertinib) combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The primary outcome measured will be progression free survival.

Criteria:

Must Have Pathologically-Confirmed Diagnosis Of Advanced Non-Squamous, Non-Small Cell Lung Cancer (Nsclc), Ecog 0-2, Adequate Organ Function Per Protocol, Hiv/Hbv/Hcv Must Have Undetectable Viral Load, No Prior Treatment With An Egfr Tki Or With An Anti-Vegf Agent, No Prior Systemic Treatment For Metastatic Disease, No Hypersensitivity To Active Or Inactive Excipients Of Osimertinib. No Evidence Of Severe Or Uncontrolled Systemic Diseases, Including Uncontrolled Hypertension And Active Bleeding Diatheses, Which In The Investigator's Opinion Makes It Challenging For The Patient To Participate In The Study.

Keywords:

Lung Cancer, Nsclc

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.